Bristol-Myers inks a $74B deal to buy out Celgene, expects $15B a year from late-stage pipeline
In a stunning turn of events, Bristol-Myers Squibb $BMY has struck a deal to buy Celgene $CELG for $74 billion in cash and stock. And several analysts were quick to agree that this was a good deal for Celgene’s bruised investors.
Celgene shareholders will get 1 share of Bristol-Myers stock and $50 for every share of the biotech they own. The acquisition is valued at $102.43 per Celgene share — plus a CVR.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.